Application 209191
- Type
- NDA
- Sponsor
- HOSPIRA INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | BORTEZOMIB | BORTEZOMIB | POWDER;INTRAVENOUS, SUBCUTANEOUS | 2.5MG/VIAL | Yes | No |
| 002 | BORTEZOMIB | BORTEZOMIB | POWDER;INTRAVENOUS, SUBCUTANEOUS | 1MG/VIAL | Yes | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N209191-001 | BORTEZOMIB | BORTEZOMIB | 1MG/VIAL | POWDER / INTRAVENOUS, SUBCUTANEOUS | AP | RLD, RS | 2022-05-02 |
| N209191-002 | BORTEZOMIB | BORTEZOMIB | 2.5MG/VIAL | POWDER / INTRAVENOUS, SUBCUTANEOUS | AP | RLD, RS | 2022-05-02 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N209191-001 | AP |
| N209191-002 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N209191-001 | BORTEZOMIB | 1MG/VIAL | POWDER / INTRAVENOUS, SUBCUTANEOUS | AP | RLD, RS | 2022-05-02 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N209191-002 | BORTEZOMIB | 2.5MG/VIAL | POWDER / INTRAVENOUS, SUBCUTANEOUS | AP | RLD, RS | 2022-05-02 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N209191-001 | AP | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N209191-002 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | N209191-001 | AP | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N209191-002 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N209191-001 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N209191-002 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N209191-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N209191-002 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N209191-001 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N209191-002 | AP | 1 | 011fe1cb6892… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N209191-001 | AP | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N209191-002 | AP | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BORTEZOMIB | BORTEZOMIB | Hospira, Inc. | 9fdf6169-699f-40eb-bda1-760253062b3c | 2023-02-27 | Warnings, Adverse reactions | 209191 NDA209191 0409-1703 0409-1704 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0409-1703 | BORTEZOMIB | BORTEZOMIB | Hospira, Inc. | NDA | Current |
| 0409-1703 | BORTEZOMIB | BORTEZOMIB | Hospira, Inc. | NDA | Current |
| 0409-1704 | BORTEZOMIB | BORTEZOMIB | Hospira, Inc. | NDA | Current |
| 0409-1704 | BORTEZOMIB | BORTEZOMIB | Hospira, Inc. | NDA | Current |